Thomas Kearns, Jr. Biography and Net Worth

Director of FibroGen


Thomas F. Kearns, Jr. has served on our board of directors since November 1996, as lead independent director from June 2017 until August 2019, and as Chairperson of our board of directors from August 2019 until January 2020. Mr. Kearns is a retired Partner of The Bear Stearns Companies, Inc., an investment banking firm, where he was an investment banker in the healthcare area from 1974 until 1987. Prior to his career at Bear Stearns, Mr. Kearns worked for Merrill Lynch, an investment banking firm, from January 1959 until August 1969. Mr. Kearns was Chairman of the National Advisory Board of Carolina Performing Arts at the University of North Carolina from 2008 until 2015. Mr. Kearns was a Trustee of the University of North Carolina Foundation and Endowment Fund for 16 years. He served on the board of directors of Biomet Inc. from January 1980 until May 2005, and he served on the board of directors of Franklin Street Partners from 2013 until 2018. He received his B.A. in History from the University of North Carolina.

What is Thomas F. Kearns, Jr.'s net worth?

The estimated net worth of Thomas F. Kearns, Jr. is at least $360,575.88 as of March 11th, 2021. Mr. Kearns, Jr. owns 166,164 shares of FibroGen stock worth more than $360,576 as of March 18th. This net worth evaluation does not reflect any other assets that Mr. Kearns, Jr. may own. Learn More about Thomas F. Kearns, Jr.'s net worth.

How do I contact Thomas F. Kearns, Jr.?

The corporate mailing address for Mr. Kearns, Jr. and other FibroGen executives is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. FibroGen can also be reached via phone at (415) 978-1200 and via email at [email protected]. Learn More on Thomas F. Kearns, Jr.'s contact information.

Has Thomas F. Kearns, Jr. been buying or selling shares of FibroGen?

Thomas F. Kearns, Jr. has not been actively trading shares of FibroGen during the last ninety days. Most recently, Thomas F. Kearns, Jr. sold 13,100 shares of the business's stock in a transaction on Wednesday, September 15th. The shares were sold at an average price of $11.58, for a transaction totalling $151,698.00. Learn More on Thomas F. Kearns, Jr.'s trading history.

Who are FibroGen's active insiders?

FibroGen's insider roster includes Pat Cotroneo (CFO), Thomas Kearns, Jr. (Director), and Thane Wettig (Insider). Learn More on FibroGen's active insiders.

Are insiders buying or selling shares of FibroGen?

In the last year, FibroGen insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $95,500.00. In the last year, insiders at the biopharmaceutical company sold shares 18 times. They sold a total of 63,716 shares worth more than $1,014,059.35. The most recent insider tranaction occured on March, 7th when CEO Thane Wettig bought 50,000 shares worth more than $95,500.00. Insiders at FibroGen own 2.4% of the company. Learn More about insider trades at FibroGen.

Information on this page was last updated on 3/7/2024.

Thomas F. Kearns, Jr. Insider Trading History at FibroGen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/15/2021Sell13,100$11.58$151,698.00View SEC Filing Icon  
3/11/2021Sell18,000$35.02$630,360.00166,164View SEC Filing Icon  
3/19/2020Sell18,000$23.17$417,060.00161,464View SEC Filing Icon  
3/12/2018Sell18,000$55.00$990,000.00135,064View SEC Filing Icon  
11/15/2017Sell18,000$45.22$813,960.00156,564View SEC Filing Icon  
6/6/2017Sell18,000$28.71$516,780.00156,564View SEC Filing Icon  
11/18/2016Sell18,000$22.40$403,200.00165,564View SEC Filing Icon  
1/21/2016Sell1,572$22.08$34,709.76160,564View SEC Filing Icon  
12/24/2015Sell7,800$30.88$240,864.00162,136View SEC Filing Icon  
11/24/2015Sell3,900$29.00$113,100.00169,936View SEC Filing Icon  
11/23/2015Sell3,900$28.02$109,278.00169,936View SEC Filing Icon  
10/21/2015Sell7,800$23.83$185,874.00177,736View SEC Filing Icon  
See Full Table

Thomas F. Kearns, Jr. Buying and Selling Activity at FibroGen

This chart shows Thomas F Kearns Jr's buying and selling at FibroGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

FibroGen Company Overview

FibroGen logo
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $2.17
Low: $1.95
High: $2.36

50 Day Range

MA: $1.69
Low: $0.75
High: $2.73

2 Week Range

Now: $2.17
Low: $0.33
High: $20.90

Volume

2,554,005 shs

Average Volume

2,808,177 shs

Market Capitalization

$214.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66